Tech Company Financing Transactions
Alchemab Therapeutics Funding Round
Alchemab Therapeutics, based in London, scored $32 million in investment from DCVC Bio, Lightstone Ventures and Lilly Ventures.
Transaction Overview
Company Name
Announced On
9/9/2025
Transaction Type
Venture Equity
Amount
$32,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance ATLX-2847, a wholly-owned program for muscle atrophy derived from the platform, into clinical development. ATLX-2847 is a first-in-class program targeting the prostaglandin pathway.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
London, Undisclosed
UK
London, Undisclosed
UK
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Alchemab has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires. The platform uses well-defined patient samples, deep B cell sequencing, and computational analysis to identify convergent protective antibody responses among individuals that are susceptible but resilient to specific diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jane Osbourn
Browse more venture capital transactions:
Prev: 9/9/2025: Torus venture capital transaction
Next: 9/9/2025: Aven venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs